SAT0071 ANALYSIS OF CHRONOLOGICAL CHANGES IN JAPANESE VERSION OF HEALTH ASSESSMENT QUESTIONNAIRE SCORE AND FACTORS ASSOCIATED WITH J-HAQ REMISSION AT 5 YEARS AFTER DISEASE ONSET IN PATIENTS WITH RHEUMATOID ARTHRITIS USING THE IORRA COHORT. (June 2019)

• Record Type: Journal Article
• Authors: Abe, Mai; Tanaka, Eiichi; Inoue, Eisuke; Kawano, Mika; Sugano, Eri; Sugitani, Naohiro; Saka, Kumiko; Shimizu, Yoko; Ochiai, Moeko; Yamaguchi, Rei; Sugimoto, Naoki; Ikari, Katsunori; Nakajima, Ayako; Taniguchi, Atsuo; Yamanaka, Hisashi
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1099
• Page End: 1099
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.3597
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Recent advances in rheumatoid arthritis (RA) treatment including the introduction of biologics have greatly affected treatment strategies for RA, achieving remission as a realistic treatment target. However, few reports have been concerned chronological changes in long-term physical dysfunction among large numbers of RA patients in daily practice. Objectives: To evaluate chronological changes in Japanese version of Health Assessment Questionnaire score (J-HAQ) score and J-HAQ remission rates at 5 years after RA onset using the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort. Methods: RA patients who developed RA between 2000 and 2010 and who first visited our hospital during the year of RA onset were divided into two groups: 1) former onset group (RA onset between 2000 and 2005) and 2) recent onset group (RA onset between 2006 and 2010). J-HAQ scores and J-HAQ remission rates at baseline and at 5 years after onset were investigated for each group, and factors associated with J-HAQ remission after 5 years were assessed by logistic regression analysis. Methotrexate (MTX), corticosteroid (steroid) and biologic DMARDs user (bDMARDs) was defined as the patients if they were used each medication during the observation period. Results: The former onset group and recent onset group included 357 and 291 RA patients, respectively. For the former onset group, the average J-HAQ score/J-HAQ remission rate at baseline and 5 years after the onset were 0.659/54.6% and 0.430/71.4%, respectively. The recent onset group showed significant improvements relative to the former onset group in J-HAQ score/J-HAQ remission rates at baseline and 5 years of 0.705/52.2% and 0.316/78.4%, respectively (p=0.011/0.044). The percentage of MTX and bDMARDs users was significantly higher in the recent onset group (former vs. recent onset group; MTX: 70.9% vs. 86.6% [p<0.0001]; bDMARDs: 5.3% vs. 23.0% [p <0.0001]). Significant factors associated with achieving J-HAQ remission at 5 years after RA onset were: patients in the recent onset group (p<0.001), male (p<0.001), younger (p<0.001), lower J-HAQ score (p<0.001) at baseline, and non-steroid user (p<0.001). Conclusion: In daily practice, J-HAQ scores for RA patients remarkably improved with recent advances in RA treatment strategies. To achieve J-HAQ remission at 5 years of RA onset, beginning treatment in the early disease stage is needed to prevent deterioration of J-HAQ and treatments that avoid steroid use appear to be important. Acknowledgement: We thank all patients who participated in the IORRA survey and all of the members of the Institute of Rheumatology, Tokyo Women's Medical University, for the successful management of the IORRA cohort. Disclosure of Interests: Mai Abe: None declared, Eiichi Tanaka Speakers bureau: Abbvie, Asahi Kasei pharma co., Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Co., Eisai Pharmaceutical, Janssen Pharmaceutical K.K., Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical Co., and UCB Pharma., Eisuke Inoue: None declared, Mika Kawano: None declared, Eri Sugano: None declared, Naohiro Sugitani: None declared, Kumiko Saka: None declared, Yoko Shimizu: None declared, Moeko Ochiai: None declared, Rei Yamaguchi: None declared, Naoki Sugimoto: None declared, Katsunori Ikari: None declared, Ayako Nakajima Grant/research support from: Asahi Kasei pharma co., Chugai Pharmaceutical, Daiichi Sankyo Co., Pfizer, Kissei Pharmaceutical Co., and Mitsubishi Tanabe Pharma Corporation., Atsuo Taniguchi: None declared, Hisashi Yamanaka Grant/research support from: AbbVie, Eisai, Bristol-Meyers, Novartis, Behringer, Astellas, Kaken, Nippon-Shinyaku, Pfizer, UCB, Ayumi, Ono, Daiichi-Sankyo, Taisyo-Toyama, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, Torii, YLbio, Speakers bureau: Bristol-Meyers, Astellas, Pfizer, Daiichi-Sankyo, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, YLbio